This review article from Journal of Comparative Effectiveness Research explores the use of tetrabenazine and valbenazine in treating tardive dyskinesia (TD), a movement disorder often induced by antipsychotic drugs.
In this review, the authors highlight the recent progress in TD genetic research with a particular focus since 2011. They review genes involved in antipsychotic drug metabolism (pharmacokinetics) and those involved in drug targeting (pharmacodynamics), and provide a number of recommendations to move this area of research forward.
The Halting Antipsychotic use in Long Term care Project has highlighted a new method for successfully reducing the use of antipsychotics to control behavioral and psychological symptoms of dementia.
The efficacy and side effects of psychiatric drugs varies significantly between patients. This article discusses the potential role of pharmacogenetics in identifying risk factors and limitations of drug regimens for patients.
This article discusses issues in the management of catatonia and the need for early diagnosis and effective treatment.
Extended use of clozapine could provide a new effective alternative for treatment-resistant schizophrenia patients.
Pietro Gareri from The Regional Center for Neurogenetics at Lamezia Terme Hospital (Catanzaro, Italy) discusses the future of the use of antipsychotics to manage behavior in dementia patients.
Agranulocytosis is a severe potential side effect for schizophrenic patients precribed clozapine, meaning close montioring with invasive white blood cell counts is required. This article discusses the potential of pharmacogenomics as an alternative for evaluating patients at low or high risk of developing the condition.
This review provides an overview of the potential role of pharmacogenomics in predisposing a child to unhealthy weight gain and cardiometabolic side effects with SGA treatment.